A Study of TAK-660 in Surgical Procedures for People With Hemophilia A.

IDENTIFIERS
Trial Protocol: TAK-660-5002
Clinicaltrials.gov: NCT04941898
JapicCTI: jRCT2031210173
PURPOSE

This study is about a factor VIII medicine called Adynovate (TAK-660) used during surgery for people with hemophilia A who have low blood levels of factor VIII. The aims of this study are as follows: - To check for side effects from TAK-660. - To check how well TAK-660 controls bleeding when used routinely during surgery and other invasive procedures such as tooth extractions. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. During the study, participants will receive infusions of TAK-660 during their hospital stay for surgery according to their clinic's standard practice. The study doctors will check for bleeds and side effects from TAK-660 from surgery until discharge.

Recruiting
JP

Trial at a glance

What medical condition is being studied?   Hemophilia A
What is the trial testing?   PEGylated Recombinant Factor VIII
Are placebos part of the trial?   No
How many participants are being enrolled?   15
When is the trial being conducted?    - 

Key requirements

Sex   
All
Age   
All
Accepts Healthy Volunteers?   
No

Trial Details / Participation Requirements

CLICK TO EXPANDCLICK TO COLLAPSE
Trial Type:   Observational
Trial Arms/Groups or Cohorts:   
TAK-660 15-50 international units per kilograms (IU/kg): Participants will receive TAK-660 15-50 IU/kg slow intravenous injection every 8- 24 hours until the bleeding is resolved or wound healing.
Intervention:   PEGylated Recombinant Factor VIII
Primary Outcome Measure(s):   
Number of Participants with Adverse Events [Time Frame: Up to 30 days]
Number of Participants with Serious Adverse Events [Time Frame: Up to 30 days]
Secondary Outcome Measure(s):   
Intraoperative Hemostatic Efficacy of TAK-660 [Time Frame: Day 1 (date of surgery)]
Postoperative Hemostatic Efficacy of TAK-660 1 Day after Surgery [Time Frame: 1 Day post-surgery]
Postoperative Hemostatic Efficacy of TAK-660 at Completion of Perioperative Management [Time Frame: At completion of perioperative management (approximately 30 days after surgery)]
Entry Criteria:
Inclusion Criteria: - Participants with blood coagulation factor VIII (FVIII) deficiency who received this drug during surgery or treatment after the start date of this survey. Exclusion Criteria: - None

Trial Locations

Any
Recruiting
Any
RESULTS
Takeda Selected Site

Tokyo, Japan

Recruiting
2,960 miles (4,763 km)  awayfrom
Новосибирск, Новосибирская область
View on Map
View all (1)
Trial Protocol ID: TAK-660-5002
Back to Trial Summary